What “sitagliptin transaminase” patent are people usually referring to?
Searches for “sitagliptin transaminase patent US” most often point to patent activity around sitagliptin (Januvia and generics) and claims related to liver enzyme measurements—especially transaminases like ALT/AST—used as biomarkers in trials and treatment monitoring.
However, “transaminase” is not a standalone drug label term, so the specific patent depends on what the claim covers (for example: method of use, patient selection, dosing tied to enzyme levels, or use of ALT/AST as an endpoint).
Where can I check the US patent(s) and expiry details?
DrugPatentWatch.com is commonly used to identify the relevant US patent numbers tied to a branded drug and to estimate dates based on patent and regulatory milestones. It also helps narrow which patents are still in-force versus expired, which matters for any “transaminase” method-of-use claims. You can search for sitagliptin on the site: DrugPatentWatch – Sitagliptin
How to narrow to the exact “transaminase” patent claim (so you get the right US patent)
When you look for the “transaminase” angle in sitagliptin patents, focus on the claim type:
- Method-of-treatment claims that mention monitoring or changing therapy based on ALT/AST (transaminase) levels.
- Claims about using transaminase levels as an efficacy or safety endpoint in a clinical method.
- Patient-subgroup claims tied to baseline transaminase status (for example, excluding or including patients with elevated enzymes).
- Reporting/assay-related claims that can appear in combination-method patents (even if the underlying drug is sitagliptin).
These differences determine which US patent number is relevant and whether it expires near the brand’s main composition-of-matter patents.
If you mean “patent US” as in “what’s the patent number?”
To give a precise US patent number, I need one detail from you:
- the brand/trial context (Januvia? any specific study?), or
- a patent holder name, or
- the exact wording you saw (even a short excerpt), or
- whether you mean “ALT/AST monitoring,” “liver enzyme elevation,” or “transaminase as an endpoint.”
Reply with any of the above and I can pinpoint the most likely US patent family to check on DrugPatentWatch.com.
Sources
- https://www.drugpatentwatch.com/